Patients
ONCOLOGY, SECONDARY, REMISSION
At data cutoff date of April 30, 2021, 44 patients were enrolled in the venetoclax and azacitidine cohorts (venetoclax 100 mg [The baseline and clinical characteristics of patients who received venetoclax and azacitidine are summarized in Table Baseline and clinical characteristics of patients treated with venetoclax and azacitidineAbbreviations: ECOG, Eastern Cooperative Oncology Group; HMA, hypomethylating agent; IPSS‐R, International Prognostic Scoring System—Revised; mCR, complete remission with incomplete marrow remission; RBC, red blood cell.Other: Either primary or secondary HMA failure.Mutations assessed from bone marrow and peripheral blasts.